🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
A Global Milestone for Wellness: Chanelle McCoy Health Secures Historic Dual SFDA and European Novel Food Regulatory Approvals The Digital and Regulatory Frontier: Top 10 Technical and GMP Trends Shaping Pharma in 2026 Funding the Future: Inside the €75k Women TechEU and £10M Createch Grants for Startups and SMEs FDA Fires Warning Shot at Sanofi's Irish Plant Over Data Cover-Up and Altuviiio Quality Failings Top Universities in Ireland: Discover the Country's Leading Higher Education Institutions The Irish Startup Ecosystem: A Comprehensive Funding and Development Guide for Entrepreneurs Addiction Counsellors of Ireland Launch Strategic Plan 2026–2029 to Prepare for CORU Regulation Ireland Funds €426,000 Behavioral App for Alcohol Reduction Amid Record Treatment Demand A Global Milestone for Wellness: Chanelle McCoy Health Secures Historic Dual SFDA and European Novel Food Regulatory Approvals The Digital and Regulatory Frontier: Top 10 Technical and GMP Trends Shaping Pharma in 2026 Funding the Future: Inside the €75k Women TechEU and £10M Createch Grants for Startups and SMEs FDA Fires Warning Shot at Sanofi's Irish Plant Over Data Cover-Up and Altuviiio Quality Failings Top Universities in Ireland: Discover the Country's Leading Higher Education Institutions The Irish Startup Ecosystem: A Comprehensive Funding and Development Guide for Entrepreneurs Addiction Counsellors of Ireland Launch Strategic Plan 2026–2029 to Prepare for CORU Regulation Ireland Funds €426,000 Behavioral App for Alcohol Reduction Amid Record Treatment Demand
Markets · 15 min delay
NBI4,187.6▲ +1.14%
PFE28.42▼ -0.38%
AZN74.18▲ +0.81%
NVO103.55▲ +2.07%
ROG261.40▼ -0.55%
ABBV174.92▲ +0.29%
EUR/USD1.0842▼ -0.12%
ISEQ9,241.3▲ +0.62%
NBI4,187.6▲ +1.14%
PFE28.42▼ -0.38%
AZN74.18▲ +0.81%
NVO103.55▲ +2.07%
ROG261.40▼ -0.55%
ABBV174.92▲ +0.29%
EUR/USD1.0842▼ -0.12%
Updated 04 Jul 2026 · HPRA open data

Irish Medicines Database

Every medicine authorised for the Irish market — 10,165 products with active substances, licence holders, dosage forms and prescription status.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0–9
406 medicines starting with “O”
MedicineActive substanceLicence holderStatus
Olmesartan/Hydrochlorothiazide Krka 40 mg/25 mg film-coated tablets
PA1347/061/004
Olmesartan medoxomil, Hydrochlorothiazide KRKA, d.d., Novo mesto Marketed
Olopatadine Misom 1 mg/mL eye drops, solution
PA23148/011/001
Olopatadine hydrochloride Brown & Burk IR Limited Not marketed
Olumiant 1 mg film-coated tablets
EU/1/16/1170/017-019
Baricitinib Eli Lilly Nederland B.V.
Olumiant 2 mg film-coated tablets
EU/1/16/1170/001-008
Baricitinib Eli Lilly Nederland B.V.
Olumiant 4 mg film-coated tablets
EU/1/16/1170/009-016
Baricitinib Eli Lilly Nederland B.V.
Omacor 1000 mg Soft Capsules
PA1099/001/001
Omega-3-acid ethyl esters BASF AS Marketed
Omacor 1000 mg Soft Capsules
PPA0465/335/001
Omega-3-acid ethyl esters 90 PCO Manufacturing Ltd.
Omacor 1000 mg Soft Capsules
PPA1463/042/001
Omega-3-acid ethyl esters IMED Healthcare Ltd.,
Omeflex peri emulsion for infusion
PA0736/033/002
Isoleucine, Leucine, Lysine hydrochloride, Methionine, Phenylalanine B. Braun Melsungen AG Marketed
Omeflex plus emulsion for infusion
PA0736/039/001
Isoleucine, Leucine, Lysine hydrochloride, Methionine, Phenylalanine B. Braun Melsungen AG Marketed
Omeflex special emulsion for infusion
PA0736/040/001
Isoleucine, Leucine, Lysine hydrochloride, Methionine, Phenylalanine B. Braun Melsungen AG Marketed
Omeflex special without electrolytes emulsion for infusion
PA0736/038/001
Isoleucine, Leucine, Lysine monohydrate, Methionine, Phenylalanine B. Braun Melsungen AG Marketed
Omeprazole 10 mg Gastro-resistant Capsules, hard
PA23266/077/001
Omeprazole Viatris Limited Not marketed
Omeprazole 10 mg hard gastro-resistant capsules
PA2315/129/001
Omeprazole Accord Healthcare Ireland Ltd. Marketed
Omeprazole 20 mg Gastro-resistant Capsules, hard
PA23266/077/002
Omeprazole Viatris Limited Not marketed
Omeprazole 20 mg hard gastro-resistant capsules
PA2315/129/002
Omeprazole Accord Healthcare Ireland Ltd. Marketed
Omeprazole 40 mg Gastro-resistant Capsules, hard
PA23266/077/003
Omeprazole Viatris Limited Not marketed
Omeprazole 40 mg hard gastro-resistant capsules
PA2315/129/003
Omeprazole Accord Healthcare Ireland Ltd. Marketed
Omeprazole Bluefish 10 mg gastro-resistant capsules
PA1436/007/001
Omeprazole Bluefish Pharmaceuticals AB Marketed
Omeprazole Bluefish 20 mg gastro-resistant capsules
PA1436/007/002
Omeprazole Bluefish Pharmaceuticals AB Marketed
Omeprazole Bluefish 40 mg gastro-resistant capsules
PA1436/007/003
Omeprazole Bluefish Pharmaceuticals AB Marketed
Omeprazole Pinewood 20 mg gastro-resistant capsules, hard
PA0281/152/001
Omeprazole Pinewood Laboratories Limited Not marketed
Omeprazole Rowa 20 mg Gastro-resistant Capsules, hard
PA0074/075/002
Omeprazole Rowa Pharmaceuticals Limited, Marketed
Omeprazole Rowa 40 mg Gastro-Resistant Capsules, hard
PA0074/075/003
Omeprazole Rowa Pharmaceuticals Limited, Marketed
Omeprazole Teva 10 mg gastro-resistant capsules, hard
PA0749/160/001
Omeprazole Teva Pharma B.V. Marketed
Omeprazole Teva 20 mg gastro-resistant capsules, hard
PA0749/160/002
Omeprazole Teva Pharma B.V. Marketed
Omeprazole Teva 40 mg Gastro-resistant Capsules, hard
PA0749/160/003
Omeprazole Teva Pharma B.V. Marketed
Omesar 10 mg film-coated tablets
PA0865/011/001
Olmesartan medoxomil Menarini International Operations Luxembourg S.A. Marketed
Omesar 20 mg film-coated tablets
PA0865/011/002
Olmesartan medoxomil Menarini International Operations Luxembourg S.A. Marketed
Omesar 40 mg film-coated tablets
PA0865/011/003
Olmesartan medoxomil Menarini International Operations Luxembourg S.A. Marketed
Omesar Plus 20 mg/12.5 mg film-coated tablets
PA0865/014/001
Olmesartan medoxomil, Hydrochlorothiazide Menarini International Operations Luxembourg S.A. Marketed
Omesar Plus 20 mg/25 mg film-coated tablets
PA0865/014/002
Olmesartan medoxomil, Hydrochlorothiazide Menarini International Operations Luxembourg S.A. Marketed
Omesar Plus 40 mg/12.5 mg film-coated tablets
PA0865/014/003
Olmesartan medoxomil, Hydrochlorothiazide Menarini International Operations Luxembourg S.A. Marketed
Omesar Plus 40 mg/25 mg film-coated tablets
PA0865/014/004
Olmesartan medoxomil, Hydrochlorothiazide Menarini International Operations Luxembourg S.A. Marketed
Omidria 10 mg/ml + 3 mg/ml concentration for solution for intraocular irrigation
EU/1/15/1018/001
Phenylephrine hydrochloride, Ketorolac trometamol Rayner Surgical (Ireland) Limited
Omjjara 100 mg film-coated tablets
EU/1/23/1782/001
Momelotinib Dihydrochloride Monohydrate GlaxoSmithKline Trading Services Limited
Omjjara 150 mg film-coated tablets
EU/1/23/1782/002
Momelotinib Dihydrochloride Monohydrate GlaxoSmithKline Trading Services Limited
Omjjara 200 mg film-coated tablets
EU/1/23/1782/003
Momelotinib Dihydrochloride Monohydrate GlaxoSmithKline Trading Services Limited
Omlyclo 150 mg solution for injection in pre-filled syringe
EU/1/24/1817/002-004
Omalizumab Celltrion Healthcare Hungary Kft.
Omlyclo 75 mg solution for injection in pre-filled syringe
EU/1/24/1817/001
Omalizumab Celltrion Healthcare Hungary Kft.
Omnexel, 400 micrograms prolonged release tablets, film-coated
PPA0465/171/001
Tamsulosin hydrochloride PCO Manufacturing Ltd.
Omnexel®, 400 micrograms prolonged release tablets, film-coated
PA1241/006/001
Tamsulosin hydrochloride Astellas Pharma Co. Limited Marketed
Omnexel®, 400 micrograms prolonged release tablets, film-coated
PPA1463/025/001
Tamsulosin hydrochloride IMED Healthcare Ltd.,
Omnipaque 140 mg I/ml Solution for Injection (Glass)
PA0735/006/001
Iohexol GE Healthcare AS Not marketed
Omnipaque 180 mg I/ml Solution for Injection (Glass)
PA0735/006/002
Iohexol GE Healthcare AS Marketed
Omnipaque 240 mg I/ml Solution for Injection (Glass)
PA0735/006/004
Iohexol GE Healthcare AS Marketed
Omnipaque 240 mg I/ml Solution for Injection (Polypropylene)
PA0735/006/023
Iohexol GE Healthcare AS Marketed
Omnipaque 300 mg I/ml Solution for Injection (Glass)
PA0735/006/008
Iohexol GE Healthcare AS Marketed
Omnipaque 300 mg I/ml Solution for Injection (Polypropylene)
PA0735/006/018
Iohexol GE Healthcare AS Marketed
Omnipaque 350 mg I/ml Solution for Injection (Glass)
PA0735/006/013
Iohexol GE Healthcare AS Not marketed
1 2 3 4 5 6 7

Data: Health Products Regulatory Authority (HPRA) open dataset (“Authorised or Transfer Pending Products”), licensed CC BY 4.0, refreshed daily. Regulatory information only — not medical advice.